US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
US7041289B1
(en)
|
1997-12-05 |
2006-05-09 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for treating established spontaneous auto-immune diseases in mammals
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
RU2312860C2
(ru)
|
1999-04-15 |
2007-12-20 |
Бристол-Маерс Сквибб Компани |
Циклические ингибиторы протеинтирозинкиназ
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
AUPQ431299A0
(en)
|
1999-11-26 |
1999-12-23 |
Unisearch Limited |
Method of inducing immune tolerance
|
DK1235830T3
(da)
|
1999-12-10 |
2004-03-29 |
Pfizer Prod Inc |
Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
|
US20020006403A1
(en)
|
1999-12-14 |
2002-01-17 |
Xue-Zhong Yu |
CD28-specific antibody compositions for use in methods of immunosuppression
|
DE10001372A1
(de)
|
2000-01-14 |
2001-08-02 |
Deutsches Krebsforsch |
Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
|
AU3108001A
(en)
|
2000-01-20 |
2001-12-24 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
US7395158B2
(en)
|
2000-05-30 |
2008-07-01 |
Sensys Medical, Inc. |
Method of screening for disorders of glucose metabolism
|
ES2586206T3
(es)
|
2000-06-19 |
2016-10-13 |
Beth Israel Deaconess Medical Center |
Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T
|
EE200200711A
(et)
|
2000-06-26 |
2004-06-15 |
Pfizer Products Inc. |
Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
|
WO2002016414A2
(en)
|
2000-08-22 |
2002-02-28 |
Micromet Ag |
Composition for the elimination of autoreactive b-cells
|
KR20080014934A
(ko)
|
2000-11-07 |
2008-02-14 |
노파르티스 아게 |
단백질 키나제 c 억제제로서의 인돌릴말레이미드 유도체
|
AU2002305716B2
(en)
|
2001-05-23 |
2007-10-25 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
|
CN1195779C
(zh)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
GT200200234A
(es)
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
AU2003208839A1
(en)
|
2002-02-13 |
2003-09-04 |
Micromet Ag |
De-immunized (poly)peptide constructs
|
US20030216551A1
(en)
|
2002-03-08 |
2003-11-20 |
Diabetogen Biosciences Inc. |
Fully human anti-CD3 monoclonal antibodies
|
KR100517056B1
(ko)
|
2002-04-15 |
2005-09-27 |
재단법인 목암생명공학연구소 |
하이드록실 페닐 유도체, 그의 제조방법 및 그를 포함하는약학적 조성물
|
DE60329724D1
(de)
|
2002-06-07 |
2009-11-26 |
Waratah Pharmaceuticals Inc |
Methoden und Kompositionen um Diabetes zu behandeln
|
EP1837031B1
(en)
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
WO2003105897A1
(en)
|
2002-06-14 |
2003-12-24 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
US20030235583A1
(en)
|
2002-06-14 |
2003-12-25 |
Jeppe Sturis |
Combined use of a modulator of CD3 and a beta cell resting compound
|
ES2559763T3
(es)
|
2002-09-10 |
2016-02-15 |
Affimed Gmbh |
Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
AU2003283004A1
(en)
|
2002-10-22 |
2004-05-13 |
Waratah Pharmaceuticals, Inc. |
Treatment of diabetes
|
AU2003295471B2
(en)
|
2002-11-15 |
2011-08-25 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
ES2729974T3
(es)
|
2003-01-23 |
2019-11-07 |
Ono Pharmaceutical Co |
Anticuerpo específico de PD-1 y CD3 humanas
|
US20060235201A1
(en)
|
2003-02-06 |
2006-10-19 |
Roman Kischel |
Enduring T cell response
|
US7196093B2
(en)
|
2003-04-09 |
2007-03-27 |
General Atomics |
Reversible inhibitors of SAH hydrolase and uses thereof
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
US7635472B2
(en)
|
2003-05-31 |
2009-12-22 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
NZ543202A
(en)
|
2003-05-31 |
2008-04-30 |
Micromet Ag |
Pharmaceutical composition comprising a bispecific antibody for epcam
|
CN1822857A
(zh)
|
2003-06-02 |
2006-08-23 |
阿莱克申药物公司 |
去免疫原性抗cd3抗体
|
EP1644370A4
(en)
|
2003-07-11 |
2008-06-04 |
Bristol Myers Squibb Co |
TETRAHYDROCHINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
WO2005037199A2
(en)
|
2003-10-10 |
2005-04-28 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
US20050176028A1
(en)
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
KR101229731B1
(ko)
|
2003-10-16 |
2013-03-07 |
암젠 리서치 (뮌헨) 게엠베하 |
다중특이적 탈면역화된 cd3-바인더
|
US20070053954A1
(en)
|
2003-10-24 |
2007-03-08 |
Rowe Stephen C |
Macromer-melt formulations
|
WO2005040163A1
(en)
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
EP1687066B1
(en)
|
2003-11-14 |
2012-08-29 |
Brigham and Women's Hospital, Inc. |
Methods of modulating immunity
|
US20050147581A1
(en)
|
2003-11-19 |
2005-07-07 |
The Board Of Trustees Of The University Of Illinois |
Macromolecular drug complexes having improved stability and therapeutic use of the same
|
DK1691833T3
(da)
|
2003-11-28 |
2010-05-03 |
Micromet Ag |
Præparater der omfatter polypeptider
|
BRPI0417820A
(pt)
|
2003-12-19 |
2007-03-27 |
Bristol Myers Squibb Co |
heterociclos azabicìclicos como moduladores de receptor canabinóide
|
RU2006126122A
(ru)
|
2003-12-19 |
2008-01-27 |
Бристол-Маерс Сквибб Компани (Us) |
Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
AU2005213449A1
(en)
|
2004-02-04 |
2005-08-25 |
The La Jolla Institute For Allergy And Immunology |
Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
|
SI1716178T1
(sl)
|
2004-02-16 |
2010-11-30 |
Micromet Ag |
Manj imunogene vezne molekule
|
WO2005079840A2
(en)
|
2004-02-20 |
2005-09-01 |
Develogen Aktiengesellschaft |
Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
US20050250691A1
(en)
|
2004-05-10 |
2005-11-10 |
Diamyd Therapeutics Ab |
Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
|
EP1755631A2
(en)
|
2004-03-03 |
2007-02-28 |
Diamyd Medical AB |
Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
|
JP5848861B2
(ja)
|
2004-04-20 |
2016-01-27 |
ジェンマブ エー/エスGenmab A/S |
Cd20に対するヒトモノクローナル抗体
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
US7592313B2
(en)
|
2004-05-17 |
2009-09-22 |
Board Of Trustees Of The University Of Illinois |
Method of stimulating proliferation of regulatory T cells in a diabetic mammal
|
US7728114B2
(en)
|
2004-06-03 |
2010-06-01 |
Novimmune S.A. |
Anti-CD3 antibodies and methods of use thereof
|
WO2006002532A1
(en)
|
2004-07-01 |
2006-01-12 |
Waratah Pharmaceuticals, Inc. |
Methods and compositions using cd3 agonists
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
MX2007002188A
(es)
|
2004-08-30 |
2007-10-16 |
Schering Ag |
Tratamiento de infecciones por vih mediante modulacion de celulas t.
|
EP1799840A4
(en)
|
2004-09-03 |
2009-02-18 |
Univ Columbia |
ILT3-POLYPEPTIDES AND USES THEREOF
|
US20070264229A1
(en)
|
2004-09-13 |
2007-11-15 |
Strominger Jack L |
Peptides for Treatment of Autoimmune Disease
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
EP1815865A4
(en)
|
2004-11-08 |
2010-08-25 |
Ono Pharmaceutical Co |
THERAPEUTIC AGENT AGAINST DIABETES WITH A PROTEASE-INHIBITING COMPOUND
|
CA2589374C
(en)
|
2004-11-30 |
2016-05-03 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
CA2596332A1
(en)
|
2005-02-04 |
2006-08-10 |
Dow Agrosciences, Llc |
Anti-t cell and autoantigen treatment of autoimmune disease
|
JP2008531730A
(ja)
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
US20130039861A1
(en)
|
2005-04-06 |
2013-02-14 |
Immunomedics, Inc. |
Dye Conjugated Peptides for Fluorescent Imaging
|
KR101235484B1
(ko)
|
2005-04-06 |
2013-02-22 |
브리스톨-마이어스 스큅 컴퍼니 |
가용성 ctla4 돌연변이체 분자를 이용하여 이식편이식과 연관된 면역 장애를 치료하는 방법
|
US7968535B2
(en)
|
2005-05-04 |
2011-06-28 |
Develogen Atkiengesellschaft |
Use of azapaullones for preventing and treating pancreatic autoimmune disorders
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
US7393919B2
(en)
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
EP2497496A3
(en)
|
2005-07-11 |
2013-02-20 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
WO2007033230A2
(en)
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-cd3 antibody formulations
|
US20070190052A1
(en)
|
2005-09-14 |
2007-08-16 |
The Trustees Of Columbia University In The City Of New York |
Regulatory CD8cells induced with anti-CD3 antibody
|
WO2007038687A2
(en)
|
2005-09-27 |
2007-04-05 |
Aciont, Inc. |
Ocular administration of immunosuppressive agents
|
CA2631598C
(en)
|
2005-11-29 |
2017-06-27 |
Actogenix Nv |
Induction of mucosal tolerance to antigens
|
US8466263B2
(en)
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
MX2008007287A
(es)
|
2005-12-08 |
2008-10-27 |
Univ Louisville Res Found |
Metodos y composiciones para expandir celulas reguladoras t.
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
DK1976886T3
(en)
|
2005-12-16 |
2015-03-02 |
Amgen Res Munich Gmbh |
Means and methods for the treatment of tumor diseases
|
EP1981532A4
(en)
|
2005-12-21 |
2010-06-30 |
Medimmune Llc |
EPHA2 MOLECULES AND USES THEREOF
|
DK1976880T3
(en)
|
2005-12-21 |
2016-09-26 |
Amgen Res (Munich) Gmbh |
Pharmaceutical compositions with resistance to soluble cea
|
WO2007084775A2
(en)
|
2006-01-20 |
2007-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulation of suppressor t cell activation
|
GB0605702D0
(en)
|
2006-03-21 |
2006-05-03 |
Biotransformations Ltd |
Materials and methods for immune cell stimulation
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
吡咯并嘧啶化合物及其用途
|
WO2007145941A2
(en)
|
2006-06-06 |
2007-12-21 |
Tolerrx, Inc. |
Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
|
SG177907A1
(en)
*
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
EP1880729A1
(en)
|
2006-07-20 |
2008-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of soluble CD160 to suppress immunity
|
US20080026378A1
(en)
|
2006-07-28 |
2008-01-31 |
Gian Franco Bottazzo |
Prediction and prophylactic treatment of type 1 diabetes
|
ES2902063T3
(es)
|
2006-09-08 |
2022-03-24 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleucina-13
|
EP2066174B1
(en)
|
2006-09-12 |
2017-11-08 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions containing alpha-1-antitrypsin and methods for use
|
CN101164538B
(zh)
|
2006-10-16 |
2011-12-14 |
中国医学科学院基础医学研究所 |
羧胺三唑类化合物及其盐在制备治疗疼痛性疾病和/或炎症性疾病的药物中的应用
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
EP2815750A1
(en)
|
2006-12-21 |
2014-12-24 |
Vertex Pharmaceuticals Incorporated |
5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
|
US20100015142A1
(en)
|
2006-12-21 |
2010-01-21 |
Macrogenics Inc. |
Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
|
US8398956B2
(en)
|
2007-01-11 |
2013-03-19 |
Immunomedics, Inc. |
In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
|
EP2125895B1
(en)
|
2007-02-02 |
2015-04-08 |
Vegenics Pty Ltd |
Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
|
US20100129361A1
(en)
|
2007-05-01 |
2010-05-27 |
The Brigham And Women's Hospital |
Immunosuppression with antibody against itm2a
|
WO2008138017A2
(en)
|
2007-05-08 |
2008-11-13 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for modifying t cell immune responses and inflammation
|
US20110300142A1
(en)
|
2007-05-25 |
2011-12-08 |
Salford Leif G |
Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
|
WO2009023566A2
(en)
|
2007-08-09 |
2009-02-19 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
NZ599756A
(en)
|
2007-08-30 |
2013-09-27 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
CA2707483A1
(en)
|
2007-11-30 |
2009-06-11 |
Wolfgang Fraunhofer |
Protein formulations and methods of making same
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
US9309313B2
(en)
|
2008-01-09 |
2016-04-12 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of ocular inflammatory disorders
|
PL2993186T3
(pl)
|
2008-03-14 |
2020-02-28 |
Biocon Limited |
Przeciwciało monoklonalne i sposób jego otrzymywania
|
WO2009132058A2
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
SG172754A1
(en)
|
2008-10-10 |
2011-08-29 |
Trubion Pharmaceuticals Inc |
Tcr complex immunotherapeutics
|
PT3330293T
(pt)
|
2008-11-07 |
2019-10-18 |
Amgen Res Munich Gmbh |
Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
|
KR101695327B1
(ko)
|
2008-11-07 |
2017-01-11 |
암젠 리서치 (뮌헨) 게엠베하 |
급성 림프구성 백혈병의 치료방법
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
WO2010065491A2
(en)
|
2008-12-01 |
2010-06-10 |
Carolus Therapeutics, Inc. |
Methods of treating inflammatory disorders
|
WO2010088522A2
(en)
|
2009-01-30 |
2010-08-05 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and uses therefor
|
WO2010106542A2
(en)
|
2009-03-19 |
2010-09-23 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
USE OF NKp46 FOR PREVENTING DIABETES
|
RU2011148913A
(ru)
|
2009-05-01 |
2013-06-10 |
Эбботт Лэборетриз |
Иммуноглобулин с двумя вариабельными доменами и его применение
|
WO2011011706A2
(en)
|
2009-07-24 |
2011-01-27 |
The Johns Hopkins University |
Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US8398966B2
(en)
|
2009-10-15 |
2013-03-19 |
Abbvie Inc. |
IL-1 binding proteins
|
EP2490719A4
(en)
|
2009-10-20 |
2013-11-06 |
Glaxo Group Ltd |
METHOD FOR THE USE OF ANTIBODIES TO CD3 FOR PREVENTING WEIGHT INCREASE
|
JP2013508392A
(ja)
|
2009-10-20 |
2013-03-07 |
グラクソ グループ リミテッド |
自己免疫疾患における抗cd3抗体の投薬
|
CN107227335A
(zh)
|
2009-10-27 |
2017-10-03 |
安进研发(慕尼黑)股份有限公司 |
用于施用CD19xCD3双特异性抗体的给药方案
|
US20110165161A1
(en)
|
2009-12-23 |
2011-07-07 |
Shih-Yao Lin |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
WO2011120135A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
US8557961B2
(en)
|
2010-04-02 |
2013-10-15 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
JP2013523153A
(ja)
|
2010-04-07 |
2013-06-17 |
アッヴィ・インコーポレイテッド |
TNF−α結合タンパク質
|
US20130115207A1
(en)
|
2010-04-09 |
2013-05-09 |
The General Hospital Corporation |
Methods for the treatment of autoimmune diseases
|
AU2011246893A1
(en)
|
2010-04-29 |
2012-11-08 |
Hadasit Medical Research Service And Development Co. Ltd. |
Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy
|
SI2571532T1
(sl)
|
2010-05-14 |
2017-10-30 |
Abbvie Inc. |
Proteini, ki vežejo IL-1
|
WO2011156740A2
(en)
|
2010-06-10 |
2011-12-15 |
Myra Lipes |
Diagnosis of myocardial autoimmunity in heart disease
|
NZ603581A
(en)
|
2010-06-19 |
2015-05-29 |
Sloan Kettering Inst Cancer |
Anti-gd2 antibodies
|
WO2011163566A2
(en)
|
2010-06-25 |
2011-12-29 |
Tolerx, Inc. |
Methods of treating patients with immune-related diseases
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
KR102173938B1
(ko)
|
2010-08-18 |
2020-11-04 |
테레사 데이셔 |
림프양 조직에 줄기 세포와 조상 세포 결합을 저해하고, 그리고 림프 조직에서 배 중심을 재생하기 위한 조성물과 방법
|
US20120088678A1
(en)
|
2010-09-08 |
2012-04-12 |
Sanford-Burnham Medical Research Institute |
Method for prediction of response to rheumatoid arthritis therapeutics
|
US20130225427A1
(en)
|
2010-09-08 |
2013-08-29 |
Sanford-Burnham Medical Research Institute |
Method for prediction of response to immune mediated disease therapeutics
|
CN107050456B
(zh)
|
2010-09-28 |
2022-08-12 |
加利福尼亚大学董事会 |
治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
|
DK2632954T4
(da)
|
2010-10-27 |
2021-08-09 |
Amgen Res Munich Gmbh |
Midler og fremgangsmåder til behandling af dlbcl
|
US20120263722A1
(en)
|
2010-11-04 |
2012-10-18 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
CN103533943B
(zh)
|
2010-11-10 |
2018-02-13 |
安进研发(慕尼黑)股份有限公司 |
由cd3特异性结合结构域导致的不良作用的预防
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
AR084210A1
(es)
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
UY33827A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión a media-inmunoglobulina y sus usos
|
UY33826A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión con dominios trivariables y sus usos
|
CN103596591B
(zh)
|
2011-02-08 |
2016-08-24 |
Abbvie公司 |
骨关节炎和疼痛的治疗
|
WO2012118863A1
(en)
|
2011-02-28 |
2012-09-07 |
The Schepens Eye Research Institute, Inc. |
Therapies that target autoimmunity for treating glaucoma and optic neuropathy
|
PT2683406T
(pt)
|
2011-03-11 |
2019-07-08 |
Beth Israel Deaconess Medical Ct Inc |
Anticorpos anti-cd40 e utilização dos mesmos
|
EP2691515A2
(en)
|
2011-03-31 |
2014-02-05 |
President and Fellows of Harvard College |
A unique population of regulatory t cells that regulate tissue regeneration and wound healing
|
US10239952B2
(en)
|
2011-04-01 |
2019-03-26 |
Memorial Sloan Kettering Cancer Center |
Anti-WT1/HLA bi-specific antibody
|
EP3753572A1
(en)
|
2011-04-28 |
2020-12-23 |
Amgen Research (Munich) GmbH |
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
|
SG195072A1
(en)
|
2011-05-21 |
2013-12-30 |
Macrogenics Inc |
Cd3-binding molecules capable of binding to human and non-human cd3
|
WO2012173819A2
(en)
|
2011-06-14 |
2012-12-20 |
Mayo Foundation For Medical Education And Research |
Anti-cd3 therapies
|
WO2012178160A2
(en)
|
2011-06-23 |
2012-12-27 |
University Of Florida Research Foundation, Inc. |
Materials and methods for modulating immune responses
|
WO2013012414A1
(en)
|
2011-07-18 |
2013-01-24 |
Medimmune, Llc |
Dosing regimens for treatment of cea-expressing cancers
|
CN102898527B
(zh)
|
2011-07-25 |
2016-12-21 |
三星电子株式会社 |
融合蛋白、药物组合物及预防或治疗癌症的方法
|
ES2893855T3
(es)
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
|
US8932586B2
(en)
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
CN103906514A
(zh)
|
2011-09-13 |
2014-07-02 |
拜奥迈德瓦利探索有限公司 |
用于治疗代谢障碍的组合物和方法
|
CN104023721A
(zh)
|
2011-09-21 |
2014-09-03 |
干细胞医药有限公司 |
用于治疗糖尿病的β-内酰胺化合物
|
JP2014530009A
(ja)
|
2011-09-29 |
2014-11-17 |
エーピーオー‐ティー ビー.ヴイ. |
異常細胞を標的とする多重特異性結合分子
|
EP2764362B1
(en)
|
2011-10-03 |
2018-09-05 |
Immunomedics, Inc. |
Dye conjugated peptides for fluorescent imaging
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
US20140212425A1
(en)
|
2011-12-05 |
2014-07-31 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
EP2793923B1
(en)
|
2011-12-22 |
2018-05-16 |
Medizinische Universität Wien |
Cyclotides as immunosuppressive agents
|
US20150017140A1
(en)
|
2011-12-23 |
2015-01-15 |
Anthrogenesis Corporation |
Organoids comprising decellularized and repopulated placental vascular scaffold
|
KR20200040893A
(ko)
|
2012-01-13 |
2020-04-20 |
율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 |
이중 항원-유도된 이분 기능 상보성
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
CN103372214B
(zh)
|
2012-04-13 |
2017-09-29 |
北京艾棣维欣生物技术有限公司 |
治疗和/或预防ⅰ型糖尿病的药物组合物及其应用
|
JP6348484B2
(ja)
|
2012-04-18 |
2018-06-27 |
ノグラ ファーマ リミテッド |
糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法
|
ES2672974T3
(es)
|
2012-06-01 |
2018-06-19 |
Ibc Pharmaceuticals, Inc. |
Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
|
CA2915412A1
(en)
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
EP2895203A4
(en)
|
2012-06-15 |
2016-09-28 |
Imaginab Inc |
ANTIGEN BINDING CONSTRUCTIONS FOR CD3
|
KR20150033703A
(ko)
*
|
2012-06-27 |
2015-04-01 |
오르반 바이오테크 엘엘씨 |
당뇨병 치료를 위한 ctla4 융합 단백질
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
US9315567B2
(en)
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
US8808689B1
(en)
|
2012-09-27 |
2014-08-19 |
Perle Bioscience, Inc. |
Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
|
US9511110B2
(en)
|
2012-09-27 |
2016-12-06 |
Perle Bioscience, Inc. |
Generation of new pancreatic beta cells
|
WO2014075788A1
(en)
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents for treatment of claudin expressing cancer diseases
|
US9562110B2
(en)
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
WO2014085154A1
(en)
|
2012-11-27 |
2014-06-05 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating renal disease
|
US10329350B2
(en)
|
2012-12-26 |
2019-06-25 |
Industrial Technology Research Institute |
Method for producing a multivalent fab fragment with collagen-like peptide
|
JP6605957B2
(ja)
|
2013-01-04 |
2019-11-13 |
シトムクス セラピューティクス,インコーポレイティド |
生体系におけるプロテアーゼ活性を検出するための組成物及び方法
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
US20140234405A1
(en)
|
2013-02-15 |
2014-08-21 |
Claresa Levetan |
Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
|
US20140235552A1
(en)
|
2013-02-15 |
2014-08-21 |
Claresa Levetan |
Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
|
WO2014152795A2
(en)
|
2013-03-14 |
2014-09-25 |
Schentag Jerome J |
Cholestosome vesicles for incorporation of molecules into chylomicrons
|
US9732150B2
(en)
|
2013-03-14 |
2017-08-15 |
Alderbio Holdings Llc |
Therapeutic use of antibodies to HGF
|
AR095596A1
(es)
|
2013-03-15 |
2015-10-28 |
Amgen Res (Munich) Gmbh |
Moléculas de unión de cadena única comprendiendo n-terminal abp
|
JP6480907B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
多量体化技術
|
BR112015023267B1
(pt)
|
2013-03-15 |
2023-01-31 |
Epigen Biosciences, Inc |
Composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido
|
KR102207859B1
(ko)
|
2013-03-15 |
2021-01-27 |
메모리얼 슬로안 케터링 캔서 센터 |
고 친화도 항-gd2 항체
|
GB201305714D0
(en)
|
2013-03-28 |
2013-05-15 |
Ucl Business Plc |
Method
|
CA2812016A1
(en)
*
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CA3205855A1
(en)
|
2013-04-16 |
2014-10-23 |
Orbsen Therapeutics Limited |
Medical use of syndecan-2
|
PL3030232T3
(pl)
|
2013-04-29 |
2022-11-07 |
Medregen, Llc |
Gojenie ran poprzez autologiczną mobilizację komórek macierzystych
|
WO2015172800A1
(en)
|
2014-05-12 |
2015-11-19 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
SG11201509361TA
(en)
|
2013-05-28 |
2015-12-30 |
Numab Ag |
Novel antibodies
|
ES2687094T3
(es)
|
2013-07-23 |
2018-10-23 |
Novaliq Gmbh |
Composiciones estabilizadas de anticuerpos
|
HRP20220553T1
(hr)
|
2013-07-25 |
2022-06-10 |
Cytomx Therapeutics Inc. |
Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
|
CN104342453A
(zh)
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗pd−1抗体並びにその治療及び診断のための使用
|
ES2773306T3
(es)
|
2013-09-16 |
2020-07-10 |
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh |
Polipéptidos bi o multiespecíficos de unión a antígenos de superficie de células efectoras inmunitarias y antígenos de VHB para tratar infecciones por VHB y estados asociados
|
GB201317928D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
PE20160724A1
(es)
|
2013-11-04 |
2016-08-04 |
Glenmark Pharmaceuticals Sa |
Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
|
EP3068891A1
(en)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
WO2015073833A1
(en)
|
2013-11-15 |
2015-05-21 |
Pharmacyclics, Inc. |
Methods for delaying or preventing the onset of type 1 diabetes
|
US20160287622A1
(en)
|
2013-11-18 |
2016-10-06 |
Massachusetts Institute Of Technology |
Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
|
EP2878308B1
(en)
|
2013-12-02 |
2018-10-31 |
Thomas Harder |
Agents and methods for the suppression of T cell activation
|
SI3318565T1
(sl)
|
2013-12-05 |
2021-07-30 |
Pfizer Inc. |
Pirolo(2,3-D)pirimidinil, pirolo(2,3-B)pirazinil in pirolo(2,3-D)piridinil akrilamidi
|
DK3083689T3
(da)
|
2013-12-17 |
2020-08-03 |
Genentech Inc |
Anti-CD3-antistoffer og fremgangsmåder til anvendelse
|
CN106103476B
(zh)
|
2013-12-24 |
2020-11-27 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
JP6706578B2
(ja)
|
2013-12-30 |
2020-06-10 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
タンデム型Fab免疫グロブリン及びその使用
|
WO2015103319A1
(en)
|
2013-12-31 |
2015-07-09 |
Heron Therapeutics, Inc. |
Polymer-based compositions for extended release of proteins
|
WO2015112534A2
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
DK3105252T3
(da)
|
2014-02-12 |
2019-10-14 |
Michael Uhlin |
Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
|
US9321812B2
(en)
|
2014-03-28 |
2016-04-26 |
Perle Bioscience |
Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
|
CN106459971B
(zh)
|
2014-04-08 |
2019-08-16 |
弗劳恩霍夫应用研究促进协会 |
用于治疗自身免疫性疾病的联合疗法
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
CN113549153A
(zh)
|
2014-05-29 |
2021-10-26 |
宏观基因有限公司 |
三特异性结合分子和其使用方法
|
EP2955196A1
(en)
|
2014-06-10 |
2015-12-16 |
Effimune |
Antibodies directed against CD127
|
US20170218091A1
(en)
|
2014-07-03 |
2017-08-03 |
Abbvie Inc. |
Monovalent binding proteins
|
US9777073B2
(en)
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
CN106999556B
(zh)
|
2014-07-21 |
2021-07-30 |
武汉友芝友生物制药有限公司 |
细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗
|
GB201413240D0
(en)
|
2014-07-25 |
2014-09-10 |
Hansa Medical Ab |
Method
|
CN107124884B
(zh)
|
2014-07-25 |
2022-11-01 |
纪念斯隆-凯特林癌症中心 |
双特异性her2和cd3结合分子
|
US11820832B2
(en)
|
2014-07-25 |
2023-11-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
JP6431721B2
(ja)
*
|
2014-08-13 |
2018-11-28 |
学校法人大阪医科薬科大学 |
劇症1型糖尿病の検出方法及びバイオマーカー並びにキット
|
WO2016027253A1
(en)
|
2014-08-21 |
2016-02-25 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as rip1 kinase inhibitors as medicaments
|
AU2015306621B2
(en)
|
2014-08-27 |
2021-05-06 |
Memorial Sloan Kettering Cancer Center |
Antibodies, compositions, and uses
|
US11029317B2
(en)
|
2014-09-18 |
2021-06-08 |
The Johns Hopkins University |
Compositions and methods for detecting anti-endothelial cell antibodies in allograft rejection
|
WO2016044252A2
(en)
|
2014-09-19 |
2016-03-24 |
Siwa Corporation |
Anti-age antibodies for treating inflammation and auto-immune disorders
|
US10272050B2
(en)
|
2014-10-14 |
2019-04-30 |
The Brigham And Women's Hospital, Inc. |
Nanoparticles and methods of use
|
WO2016065306A1
(en)
|
2014-10-23 |
2016-04-28 |
The Brigham And Women's Hospital, Inc. |
Amphiphile-polymer particles
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
JP6779873B2
(ja)
|
2014-11-12 |
2020-11-04 |
メモリアル スローン ケタリング キャンサー センター |
抗コンドロイチン硫酸プロテオグリカン4抗体およびその使用
|
CR20170309A
(es)
|
2014-12-05 |
2018-02-02 |
Celgene Corp |
Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
|
WO2016089610A1
(en)
|
2014-12-06 |
2016-06-09 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
NZ732073A
(en)
|
2014-12-08 |
2019-04-26 |
1Globe Biomedical Co Ltd |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
US10941207B2
(en)
|
2014-12-19 |
2021-03-09 |
Chiome Bioscience, Inc |
Fusion protein comprising three binding domains to 5T4 and CD3
|
US10022347B2
(en)
|
2015-01-07 |
2018-07-17 |
The United States Of America, As Represented By The Secretary Of The Navy |
Compositions and methods for diagnosis and treatment of metabolic syndrome
|
ES2824167T3
(es)
|
2015-01-23 |
2021-05-11 |
Sanofi Sa |
Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
|
CN113713091A
(zh)
|
2015-02-06 |
2021-11-30 |
新加坡国立大学 |
工程免疫细胞及其用途和生产方法
|
EP3263599A4
(en)
|
2015-02-16 |
2018-12-19 |
Pharma Foods International Co., Ltd. |
Anti-cancer agent and antimetastatic agent using fstl1, and concomitant drug for same
|
JP6784687B2
(ja)
|
2015-02-24 |
2020-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
結合誘発型転写スイッチ及びその使用方法
|
GB201503500D0
(en)
|
2015-03-02 |
2015-04-15 |
Ucl Business Plc |
Cell
|
JP2018509413A
(ja)
|
2015-03-09 |
2018-04-05 |
アルゲン−エックス ビーブイビーエー |
FcRnアンタゴニストを用いてFc含有剤の血清レベルを低下させる方法
|
JP2018512396A
(ja)
|
2015-03-09 |
2018-05-17 |
キングス・カレッジ・ロンドン |
Th1応答を増強するためのrarアルファアゴニストを用いた併用療法
|
US10772917B2
(en)
|
2015-03-11 |
2020-09-15 |
Ccs Ventures Limited |
Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (T2D)
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
US10378055B2
(en)
|
2015-04-08 |
2019-08-13 |
City Of Hope |
Methods and compositions for measuring beta cell death
|
US11000603B2
(en)
|
2015-04-14 |
2021-05-11 |
Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. |
Multi-specific binding conjugate, related pharmaceutical compositions and use
|
US10449209B2
(en)
|
2015-04-29 |
2019-10-22 |
Arterez, Llc |
Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
|
PT3288573T
(pt)
|
2015-04-30 |
2020-03-25 |
Psioxus Therapeutics Ltd |
Adenovírus oncolítico que codifica uma proteína b7
|
JP2018520642A
(ja)
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
CA3155251A1
(en)
|
2015-05-01 |
2016-11-10 |
The Regents Of The University Of California |
Glycan-dependent immunotherapeutic molecules
|
IL293719B2
(en)
|
2015-05-21 |
2023-07-01 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
HUE048284T2
(hu)
|
2015-05-29 |
2020-07-28 |
Abbvie Inc |
Anti-CD40 antitestek és alkalmazásuk
|
CN107708741A
(zh)
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
US20190135894A1
(en)
|
2015-06-25 |
2019-05-09 |
iCell Gene Therapeuticics LLC |
COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2017008844A1
(en)
|
2015-07-14 |
2017-01-19 |
Biontech Ag |
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
US11147886B2
(en)
|
2015-07-15 |
2021-10-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
SG10202101105XA
(en)
|
2015-08-13 |
2021-03-30 |
Amgen Inc |
Charged depth filtration of antigen-binding proteins
|
CN116063481A
(zh)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
人源化抗-cd40抗体及其用途
|
WO2017062920A1
(en)
|
2015-10-07 |
2017-04-13 |
Chopra Sunandini |
Nanoparticles with ph triggered drug release
|
US10752686B2
(en)
|
2015-10-30 |
2020-08-25 |
Zonhon Biopharma Institute Inc. |
Bispecific antibody binding to human CD26 and human CD3, production method therefor and use thereof
|
CN113599533A
(zh)
|
2015-11-25 |
2021-11-05 |
乐高化学生物科学股份有限公司 |
包含分支接头的抗体-药物缀合物及其相关方法
|
AU2016359234B2
(en)
|
2015-11-25 |
2022-09-08 |
Legochem Biosciences, Inc. |
Conjugates comprising peptide groups and methods related thereto
|
AU2016372576A1
(en)
|
2015-12-17 |
2018-06-21 |
Psioxus Therapeutics Limited |
Virus encoding an anti-TCR-complex antibody or fragment
|
US20180291114A1
(en)
|
2015-12-17 |
2018-10-11 |
University Of Maryland, Baltimore County |
Recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
|
JP7012645B2
(ja)
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
キメラタンパク質および免疫治療の方法
|
EP3192810A1
(en)
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
CA3011331A1
(en)
|
2016-01-14 |
2017-07-20 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
CN109071630B
(zh)
|
2016-01-15 |
2022-05-31 |
马里兰大学帕克分校 |
作为糖苷合酶的Endo-S2突变体、制备方法以及用于糖蛋白的糖工程化的用途
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
EP3416981A1
(en)
|
2016-02-18 |
2018-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor
|
US10745478B2
(en)
|
2016-02-19 |
2020-08-18 |
Dignity Health |
Antibody fusion protein and related compositions for targeting cancer
|
US20190077856A1
(en)
|
2016-03-15 |
2019-03-14 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
CA3019137A1
(en)
|
2016-04-04 |
2017-10-12 |
Chemocentryx, Inc. |
Soluble c5ar antagonists
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
US11339225B2
(en)
|
2016-05-12 |
2022-05-24 |
Asclepius (Suzhou) Technology Company Group, Co., Ltd. |
Bispecific antigen-binding construct and preparation method and use thereof
|
CN107365387B
(zh)
|
2016-05-12 |
2022-03-15 |
阿思科力(苏州)生物科技有限公司 |
一种双特异性抗原结合构建体及其制备方法和应用
|
US11414491B2
(en)
|
2016-05-18 |
2022-08-16 |
Mayo Foundation For Medical Education And Research |
Targeting PD-L1 on tumor cells
|
WO2017205726A1
(en)
|
2016-05-27 |
2017-11-30 |
Altor Bioscience Corporation |
Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
|
US20210347901A9
(en)
|
2016-06-27 |
2021-11-11 |
Agomab Therapeutics |
Methods for promoting pancreatic islet cell growth
|
IT201800000534A1
(it)
|
2018-01-03 |
2019-07-03 |
|
Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
CA3030841A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
JP6994223B2
(ja)
|
2016-07-26 |
2022-02-04 |
静岡県 |
抗b7-h4抗体
|
US20190170752A1
(en)
|
2016-08-08 |
2019-06-06 |
Beigene, Ltd. |
Method for predicting efficacy of immune checkpoint inhibitors in cancer patients
|
CN109715819A
(zh)
|
2016-08-10 |
2019-05-03 |
马里兰大学帕克分校 |
设计者α1,6-岩藻糖苷酶突变体实现完整N-糖肽和N-糖蛋白的直接核心岩藻糖基化
|
EP3502143A4
(en)
|
2016-08-19 |
2020-07-15 |
Ampsource Biopharma Shanghai Inc. |
BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
|
WO2018037416A1
(en)
|
2016-08-25 |
2018-03-01 |
Yeda Research And Development Co. Ltd. |
Methods and compositions for treating autoimmune diseases
|
AU2017319318A1
(en)
|
2016-08-29 |
2019-02-21 |
Tiziana Life Sciences Plc |
Anti-CD3 antibody formulations
|
SG11201901716TA
(en)
|
2016-08-29 |
2019-03-28 |
Psioxus Therapeutics Ltd |
Adenovirus armed with bispecific t cell engager (bite)
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
AU2017321426B2
(en)
|
2016-08-29 |
2022-09-29 |
Hackensack University Medical Center |
Methods for treating an immune disorder-related disease by reducing autoreactivity in a T cell compartment
|
KR102497742B1
(ko)
|
2016-08-30 |
2023-02-10 |
다나-파버 캔서 인스티튜트 인크. |
약물 전달 조성물 및 그의 용도
|
US11160876B2
(en)
|
2016-09-01 |
2021-11-02 |
Mayo Foundation For Medical Education And Research |
Methods and compositions for targeting t-cell cancers
|
AU2017319707B2
(en)
|
2016-09-02 |
2023-11-09 |
Intrexon Actobiotics N.V. |
Genetically modified bacteria stably expressing IL-10 and insulin
|
CA3035653A1
(en)
|
2016-09-06 |
2018-03-15 |
Mayo Foundation For Medical Education And Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
AU2017336867B2
(en)
|
2016-09-29 |
2024-03-14 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
JP7275027B2
(ja)
|
2016-10-06 |
2023-05-17 |
アムジェン インコーポレイテッド |
粘度低下タンパク質医薬製剤
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
US11220551B2
(en)
|
2016-10-19 |
2022-01-11 |
The Governing Council Of The University Of Toronto |
CD133-binding agents and uses thereof
|
AU2017348306A1
(en)
|
2016-10-27 |
2019-05-23 |
The Trustees Of Columbia University In The City Of New York |
Immunosuppressive mesenchymal cells and methods for forming same
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
WO2018120843A1
(zh)
|
2016-12-30 |
2018-07-05 |
上海近岸生物科技有限公司 |
一种三功能分子及其应用
|
EP3575319A4
(en)
|
2016-12-30 |
2021-03-10 |
Shanghai Sinobio Biotech Co., Ltd. |
BIFUNCTIONAL MOLECULE AND USE OF IT
|
US11046768B2
(en)
|
2017-01-27 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
US20200181260A1
(en)
|
2017-02-22 |
2020-06-11 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
TW202122576A
(zh)
|
2017-03-29 |
2021-06-16 |
臺北醫學大學 |
具抗原專一性的t細胞及其用途
|
WO2018178123A1
(en)
|
2017-03-29 |
2018-10-04 |
Glycotope Gmbh |
BISPECIFIC MUC-1 x PD-L1 ANTIBODIES
|
EP3619235A1
(en)
|
2017-04-11 |
2020-03-11 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
CN108728465A
(zh)
|
2017-04-14 |
2018-11-02 |
深圳新诺微环生物科技有限公司 |
一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
|
CA3059444A1
(en)
|
2017-04-14 |
2018-10-18 |
The General Hospital Corporation |
Chimeric antigen receptor t cells targeting the tumor microenvironment
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
US11807662B2
(en)
|
2017-05-16 |
2023-11-07 |
The Johns Hopkins University |
MANAbodies and methods of using
|
EP3642228A1
(en)
|
2017-06-21 |
2020-04-29 |
Gsbio, LLC |
Heterodimeric bispecific antibodies
|
US11753431B2
(en)
|
2017-07-04 |
2023-09-12 |
Intocell, Inc. |
Compounds comprising cleavable linker and uses thereof
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
US11648269B2
(en)
|
2017-08-10 |
2023-05-16 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
|
US20200181264A1
(en)
|
2017-08-11 |
2020-06-11 |
City Of Hope |
Bispecific antigen-binding molecule
|
JP2020533317A
(ja)
|
2017-09-07 |
2020-11-19 |
オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド |
特異的akt3活性化剤およびその使用
|
RS62725B1
(sr)
*
|
2017-09-08 |
2022-01-31 |
Diamyd Medical Ab |
Stratifikacija genotipa pri tretmanu i prevenciji dijabetesa
|
US20200281976A1
(en)
|
2017-10-04 |
2020-09-10 |
City Of Hope |
Prevention and treatment of gvhd and autoimmune diseases
|
JP2020536559A
(ja)
|
2017-10-12 |
2020-12-17 |
アイセル・ジーン・セラピューティクス・エルエルシー |
複数の抗原を標的とするcompoundキメラ抗原受容体(cCAR)の組成物およびその使用方法
|
FR3072880A1
(fr)
|
2017-10-30 |
2019-05-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Formulation liposomale et son utilisation en therapie anti-tumorale
|
EP3706803A4
(en)
|
2017-11-08 |
2021-08-04 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
CONJUGATES OF BIOMOLECULES AND THEIR USES
|
US20210380641A1
(en)
|
2017-11-09 |
2021-12-09 |
University Of Washington |
Self-assembling protein structures and components thereof
|
BR112020009453A2
(pt)
|
2017-11-13 |
2020-10-27 |
Extremochem, Lda. |
amidas glicosiladas neutras e ácidos glucuronidados dianiônicos como estabilizadores de moléculas biológicas
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
BR112020012374A2
(pt)
|
2017-12-22 |
2020-11-24 |
Chemocentryx, Inc. |
compostos de anel 5,5-fundido substituído por diarila como inibidores de c5ar
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
TWI804572B
(zh)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
WO2019157533A1
(en)
|
2018-02-12 |
2019-08-15 |
The General Hospital Corporation |
Chimeric antigen receptors targeting the tumor microenvironment
|
GB201805329D0
(en)
|
2018-03-30 |
2018-05-16 |
Katholieke Univ Leuven K U Leuven R&D |
Biomakers for diabetes therapy
|
SG11202009588PA
(en)
|
2018-04-02 |
2020-10-29 |
Chemocentryx Inc |
PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
|
US20210163620A1
(en)
|
2018-04-05 |
2021-06-03 |
Brian Granda |
Trispecific binding molecules against cancers and uses thereof
|
US10633458B2
(en)
|
2018-04-10 |
2020-04-28 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
US20210113519A1
(en)
|
2018-04-17 |
2021-04-22 |
Carnegie Mellon University |
Compositions and Methods for Modulating Permeability of Biological Barriers
|
BR112020022288A2
(pt)
|
2018-05-01 |
2021-02-23 |
Ambrx, Inc. |
método para otimizar a expressão de anticorpos
|
IT201800005182A1
(it)
|
2018-05-09 |
2019-11-09 |
|
siRNA contro la variante C1858T del gene PTPN22
|
SG11202010589YA
(en)
|
2018-05-14 |
2020-11-27 |
Oncoimmune Inc |
Anti-cd24 compositions and uses thereof
|
KR20210011002A
(ko)
|
2018-05-16 |
2021-01-29 |
얀센 바이오테크 인코포레이티드 |
암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법
|
EP3569617A1
(en)
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
CN112512573A
(zh)
|
2018-05-23 |
2021-03-16 |
百提威生技股份有限公司 |
双特异性t细胞衔接蛋白及其用途
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
US20200040056A1
(en)
|
2018-05-31 |
2020-02-06 |
Washington University |
Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
|
CN112912493A
(zh)
|
2018-05-31 |
2021-06-04 |
华盛顿大学 |
用于治疗癌症的嵌合抗原受体t细胞(car-t)
|
CA3098415A1
(en)
|
2018-06-07 |
2019-12-12 |
Oncoone Research & Development Gmbh |
Anti-oxmif/anti-cd3 antibody for cancer treatment
|
AU2019292580A1
(en)
|
2018-06-29 |
2021-02-04 |
Krystal Biotech, Inc. |
Compositions and methods for antibody delivery
|
WO2020001344A1
(en)
|
2018-06-29 |
2020-01-02 |
Beijing Biocytogen Co., Ltd |
ANTI-CD3e ANTIBODIES AND USES THEREOF
|
JP2021529834A
(ja)
|
2018-07-03 |
2021-11-04 |
アイエフエム デュー インコーポレイテッド |
Sting活性に関連する状態を治療するための化合物および組成物
|
US20210261646A1
(en)
|
2018-07-03 |
2021-08-26 |
Sotio, LLC |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
EP3820571A1
(en)
|
2018-07-10 |
2021-05-19 |
University of Connecticut |
Reagents and methods for treating cancer and autoimmune disease
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
EP3829636A1
(en)
|
2018-07-27 |
2021-06-09 |
NGM Biopharmaceuticals, Inc. |
Use of glucagon receptor antagonists with immunotherapeutic agent
|
CA3107675A1
(en)
|
2018-07-30 |
2020-02-06 |
University Of Southern California |
Improving the efficacy and safety of adoptive cellular therapies
|
WO2020033499A1
(en)
|
2018-08-09 |
2020-02-13 |
Duke University |
Enhanced delivery of drugs and other compounds to the brain and other tissues
|
CN112840019A
(zh)
|
2018-08-14 |
2021-05-25 |
Sotio有限责任公司 |
与调节克雷布斯循环的反式代谢分子组合的嵌合抗原受体多肽及其治疗用途
|
CN111417655A
(zh)
|
2018-08-28 |
2020-07-14 |
润俊(中国)有限公司 |
抗cd3抗体叶酸生物偶联物及其用途
|
AU2019336229A1
(en)
|
2018-09-07 |
2021-03-18 |
Sotio, LLC |
Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
|
EP3849513A1
(en)
|
2018-09-11 |
2021-07-21 |
Ichnos Sciences SA |
Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
|
EP4268831A2
(en)
|
2018-09-12 |
2023-11-01 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
WO2020056037A1
(en)
|
2018-09-13 |
2020-03-19 |
Board Of Regents Of The University Of Nebraska |
Biomarkers for type 1 diabetes
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
US20210353751A1
(en)
|
2018-10-18 |
2021-11-18 |
The Regents Of The University Of California |
Combination therapies for treatment of inflammatory diseases
|
WO2020086423A1
(en)
|
2018-10-22 |
2020-04-30 |
Icell Kealex Therapeutics |
Mutant vaccinia viruses and use thereof
|
EP3873521A2
(en)
|
2018-10-31 |
2021-09-08 |
Tiziana Life Sciences PLC |
Composition and methods of treating inflammatory and autoimmune diseases
|
CA3118397A1
(en)
|
2018-11-01 |
2020-05-07 |
Shandong Newtime Pharmaceutical Co., Ltd. |
Bispecific antibody targeting cd3 and bcma, and uses thereof
|
WO2020092743A2
(en)
|
2018-11-01 |
2020-05-07 |
Memorial Sloan Kettering Cancer Center |
Methods of treating diseases using kinase modulators
|
TW202039537A
(zh)
|
2018-11-27 |
2020-11-01 |
美商昂科賽克醫療公司 |
用於治療癌症之質體建構體和使用方法
|
EP3902834A4
(en)
|
2018-11-30 |
2022-08-24 |
Memorial Sloan Kettering Cancer Center |
HETERODIMERIC COMPOSITIONS OF SPECIFIC AND TETRAVALENT ANTIBODIES, AND USES THEREOF
|
WO2020118136A1
(en)
|
2018-12-06 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Selectively cleavable therapeutic nanoparticles
|
WO2020124032A1
(en)
|
2018-12-14 |
2020-06-18 |
Fred Hutchinson Cancer Research Center |
Transferrin receptor targeting peptides
|
WO2020123806A1
(en)
|
2018-12-14 |
2020-06-18 |
Beth Israel Deaconess Medical Center. Inc. |
Modulation of pd-1
|
KR20210104816A
(ko)
|
2018-12-19 |
2021-08-25 |
시티 오브 호프 |
Baff-r 이중특이적 t 세포 인게이저 항체
|
WO2020141460A2
(en)
|
2019-01-03 |
2020-07-09 |
Intocell, Inc. |
Compounds comprising cleavable linker and uses thereof
|
JP2022515884A
(ja)
|
2019-01-03 |
2022-02-22 |
イントゥーセル,インコーポレーティッド |
切断可能なリンカーを含む化合物及びその使用
|
WO2020150402A2
(en)
|
2019-01-15 |
2020-07-23 |
Caerus Therapeutics, Corp. |
Advanced chimeric antigen receptor vectors for targeting solid tumors
|
JP2022520163A
(ja)
|
2019-01-30 |
2022-03-29 |
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー |
癌抗原を標的とするdnaコード化二重特異性t細胞エンゲージャーおよび癌治療薬における使用方法
|
JPWO2020166592A1
(ja)
|
2019-02-13 |
2021-12-09 |
大日本住友製薬株式会社 |
ヘミアスタリン誘導体とその抗体薬物複合体
|
BR112021015907A2
(pt)
|
2019-02-20 |
2021-11-03 |
Res Institute At Nationwide Childrens Hospital |
Ligantes de células t (catvert) ou nk (catvern) direcionados a câncer, codificados por vírus e reguláveis
|
EP3929212A4
(en)
|
2019-02-22 |
2022-11-23 |
Wuhan Yzy Biopharma Co., Ltd. |
MODIFIED FC FRAGMENT, ANTIBODY COMPRISING THEM AND THEIR APPLICATION
|
WO2020168555A1
(zh)
|
2019-02-22 |
2020-08-27 |
武汉友芝友生物制药有限公司 |
Cd3抗原结合片段及其应用
|
EP3938400A4
(en)
|
2019-03-11 |
2022-11-23 |
Memorial Sloan Kettering Cancer Center |
CD22 ANTIBODIES AND METHODS OF USE THEREOF
|
CN109776683B
(zh)
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
CA3134056A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
WO2020190217A2
(en)
|
2019-03-21 |
2020-09-24 |
Agency For Science, Technology And Research |
Composition
|
CA3131052A1
(en)
|
2019-03-25 |
2020-10-01 |
Soon Jae Park |
Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase ph20 variant and drug
|
EP3947689A4
(en)
|
2019-03-27 |
2023-03-29 |
National Research Council of Canada |
ANTIGEN BINDING AGENTS THAT SPECIFICALLY BIND TO VARIANT III OF THE EPIDERMAL GROWTH FACTOR RECEPTOR
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
JP2022525435A
(ja)
|
2019-04-08 |
2022-05-13 |
メモリアル スローン ケタリング キャンサー センター |
Cd19抗体およびこれを使用する方法
|
US20220249696A1
(en)
|
2019-04-12 |
2022-08-11 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
US20220160891A1
(en)
|
2019-04-12 |
2022-05-26 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
US20220348657A1
(en)
|
2019-04-18 |
2022-11-03 |
Five Prime Therapeutics, Inc. |
Bioassay for t-cell co-stimulatory proteins containing fc domains
|
WO2020223279A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
|
CR20210578A
(es)
|
2019-04-30 |
2022-02-22 |
Sitryx Therapeutics Ltd |
Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunotaria indeseable
|
EP3966248A4
(en)
|
2019-05-08 |
2023-04-12 |
Memorial Sloan Kettering Cancer Center |
HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
|
GB201906685D0
(en)
|
2019-05-13 |
2019-06-26 |
Ultrahuman Six Ltd |
Activatable protein constructs and uses thereof
|
KR102503349B1
(ko)
*
|
2019-05-14 |
2023-02-23 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
JP2022534783A
(ja)
|
2019-06-03 |
2022-08-03 |
イミュノルクス インターナショナル コーポレーション |
疾患を処置するための天然痘ワクチン及び幹細胞
|
WO2020247871A2
(en)
|
2019-06-06 |
2020-12-10 |
Janux Therapeutics, Inc. |
Compositions and methods relating to tumor activated t cell engagers
|
AU2020300002A1
(en)
|
2019-07-01 |
2022-02-24 |
Tonix Pharma Limited |
Anti-CD154 antibodies and uses thereof
|
AU2020316422A1
(en)
|
2019-07-22 |
2022-02-17 |
University Of Florida Research Foundation, Incorporated |
Multimeric protein domains for multifunctionality and enhanced secretion of therapeutic proteins
|
US20210130464A1
(en)
|
2019-07-30 |
2021-05-06 |
Provention Bio, Inc. |
Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
|
JP2022544053A
(ja)
|
2019-07-30 |
2022-10-17 |
プロヴェンション・バイオ・インコーポレイテッド |
非枯渇性b細胞阻害剤によって免疫原性を低下させるための方法および組成物
|
JP2022548509A
(ja)
|
2019-08-27 |
2022-11-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
IL13Rα2陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成CAR
|
EP4023245A4
(en)
|
2019-08-28 |
2023-08-30 |
Azusapharma Sciences, Inc. |
BIFIDOBACTERIUM SPP. WITH EXPRESSION AND SECRETION OF DIABODY-TYPE BSAB
|
WO2021041958A1
(en)
|
2019-08-30 |
2021-03-04 |
Shattuck Labs. Inc. |
Chimeric proteins in autoimmunity
|
GB201912681D0
(en)
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
CN112480263A
(zh)
|
2019-09-12 |
2021-03-12 |
普米斯生物技术(苏州)有限公司 |
一种双特异t细胞激活器活化t细胞的设计及其应用
|
EP3791931A1
(en)
|
2019-09-13 |
2021-03-17 |
Ichnos Sciences SA |
Bispecific antibodies for the treatment of solid tumors
|
KR102081418B1
(ko)
|
2019-09-24 |
2020-05-26 |
주식회사 이뮤니스바이오 |
말초혈액단핵구 유래 조절 t 세포 배양용 조성물 및 이를 이용한 조절 t 세포 배양방법
|
WO2021064069A1
(en)
|
2019-10-02 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of adult t-cell leukemia/lymphoma
|
WO2021071319A1
(ko)
|
2019-10-10 |
2021-04-15 |
주식회사 와이바이오로직스 |
다중 특이적 융합 단백질 및 이의 용도
|
US20240093158A1
(en)
|
2019-10-10 |
2024-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic viruses that express multi-specific immune cell engagers
|
AU2020379319A1
(en)
|
2019-11-05 |
2022-06-23 |
Yeda Research And Development Co. Ltd. |
Use of veto cells in treatment of T cell mediated autoimmune diseases
|
US20230227547A1
(en)
|
2019-11-12 |
2023-07-20 |
Iprogen Biotech Inc. |
Antibody-payload conjugates with enhanced delivery domain and uses thereof
|
US20230039858A1
(en)
|
2019-12-02 |
2023-02-09 |
Intocell, Inc. |
Compositions and methods related to molecular conjugation
|
CN115943160A
(zh)
|
2019-12-06 |
2023-04-07 |
翁科奥内研发有限责任公司 |
抗oxMIF/抗CD3双特异性抗体构建体
|
EP4073067A1
(en)
|
2019-12-12 |
2022-10-19 |
Fresenius Kabi Deutschland GmbH |
Glycosylated polypeptides
|
WO2021119585A1
(en)
|
2019-12-13 |
2021-06-17 |
Dnalite Therapeutics, Inc. |
Compositions and methods for biological delivery vehicles
|
AU2020405183A1
(en)
|
2019-12-18 |
2022-06-09 |
TeneoFour, Inc. |
Heavy chain antibodies binding to CD38
|
JOP20220150A1
(ar)
|
2019-12-18 |
2023-01-30 |
Janssen Biotech Inc |
مواد وطرق للاستهداف البيولوجي في الجسم الحي
|
TW202138356A
(zh)
|
2019-12-23 |
2021-10-16 |
英商喜翠克斯治療有限公司 |
新穎之化合物
|
AU2020417305A1
(en)
|
2019-12-31 |
2022-07-21 |
Fred Hutchinson Cancer Center |
Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
|
WO2021146328A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
EP4090377A1
(en)
|
2020-01-13 |
2022-11-23 |
Synaffix B.V. |
Conjugates of antibodies an immune cell engagers
|
AU2021208642A1
(en)
|
2020-01-17 |
2022-07-28 |
Immune Targeting, Inc. |
Pro-antibody that reduces off-target toxicity
|
IL294879A
(en)
|
2020-01-29 |
2022-09-01 |
Inhibrx Inc |
Monodomain antibodies of cd28 and their multivalent and multispecific constructs
|
EP4103583A1
(en)
|
2020-02-14 |
2022-12-21 |
Chang Gung Memorial Hospital |
Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
|
EP3865513A1
(en)
|
2020-02-17 |
2021-08-18 |
Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre |
Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof
|
EP4110398A1
(en)
|
2020-02-27 |
2023-01-04 |
Phanes Therapeutics, Inc. |
Antibodies conjugated with fatty acid molecules and uses thereof
|
KR20220152316A
(ko)
|
2020-03-12 |
2022-11-15 |
이뮨-온크 테라퓨틱스, 인코포레이티드 |
신규한 항-lilrb4 항체 및 유도체 생성물
|
CN115667314A
(zh)
|
2020-03-16 |
2023-01-31 |
美真达治疗公司 |
T细胞双特异性结合蛋白
|
WO2021195067A1
(en)
|
2020-03-23 |
2021-09-30 |
Cytoarm Co. Ltd. |
Bi-specific antibodies for use in producing armed immune cells
|
CN115397515A
(zh)
|
2020-03-31 |
2022-11-25 |
弗莱德哈钦森癌症中心 |
人抗cd33抗体和其用途
|
EP4126245A2
(en)
|
2020-03-31 |
2023-02-08 |
Fred Hutchinson Cancer Center |
Anti-cd33 antibodies and uses thereof
|
MX2022012812A
(es)
|
2020-04-13 |
2023-01-30 |
Univ Health Network |
Métodos para tratar el síndrome de liberación de citocinas.
|
WO2021216460A1
(en)
|
2020-04-19 |
2021-10-28 |
Figene, Llc |
Gene modified fibroblasts for therapeutic applications
|
CN113527510A
(zh)
|
2020-04-22 |
2021-10-22 |
上海交通大学 |
融合蛋白分子及其制备方法和用途
|
EP4139347A1
(en)
|
2020-04-24 |
2023-03-01 |
Memorial Sloan Kettering Cancer Center |
Anti-cd3 antibodies and uses thereof
|
JP2023524238A
(ja)
|
2020-04-30 |
2023-06-09 |
アーチ オンコロジー,インコーポレイテッド |
治療用SIRPα抗体
|
WO2021222861A1
(en)
|
2020-04-30 |
2021-11-04 |
Children's Medical Center Corporation |
Antibodies specific to abcb5 and uses thereof
|
US20210349094A1
(en)
|
2020-05-11 |
2021-11-11 |
Musc Foundation For Research Development |
Detection of autoreactive fecal immunoglobulin a (iga) for diagnosis of lupus
|
CA3180572A1
(en)
|
2020-05-29 |
2021-12-02 |
Johan Skog |
Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection
|
IL298867A
(en)
|
2020-06-11 |
2023-02-01 |
Tizona Therapeutics |
Combines bispecific immune cells with binding specificity for HLA-G and another antigen
|
JP2023530109A
(ja)
|
2020-06-11 |
2023-07-13 |
プロヴェンション・バイオ・インコーポレイテッド |
1型糖尿病を予防するための方法および組成物
|
WO2021254574A2
(en)
|
2020-06-17 |
2021-12-23 |
Y-Mabs Therapeutics, Inc. |
Cd38 antibodies for the treatment of human diseases
|
EP4182447A1
(en)
|
2020-07-14 |
2023-05-24 |
Ichilov Tech Ltd. |
Pseudotyped viruses configured to express car in t-cells
|
WO2022018262A1
(en)
|
2020-07-24 |
2022-01-27 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
US20230270857A1
(en)
|
2020-07-28 |
2023-08-31 |
Memorial Sloan Kettering Cancer Center |
Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
|
CN116234828A
(zh)
|
2020-07-29 |
2023-06-06 |
米纳瓦生物技术公司 |
抗可变muc1*抗体及其用途
|
WO2022026939A2
(en)
|
2020-07-31 |
2022-02-03 |
Soteria Biotherapeutics, Inc. |
Single and dual targeting ligand induced t-cell engager compositions
|
US20240018111A1
(en)
|
2020-08-05 |
2024-01-18 |
Sitryx Therapeutics Limited |
Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
|
EP4192879A2
(en)
|
2020-08-06 |
2023-06-14 |
Abpro Corporation |
Anti-claudin 18.2 multi-specific antibodies and uses thereof
|
US20230303695A1
(en)
|
2020-08-10 |
2023-09-28 |
Tengfei XIAO |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
WO2022035888A2
(en)
|
2020-08-10 |
2022-02-17 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Sars-cov-2-neutralizing antibodies, biomarkers to predict protection from re-infection, and high efficiency antibody screening methods
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
CA3189708A1
(en)
|
2020-08-19 |
2022-02-24 |
Mahiuddin Ahmed |
Vaccine compositions and antibodies for lyme disease
|
US11124568B1
(en)
|
2020-08-19 |
2021-09-21 |
Vitruviae LLC |
CD3/CD25 antibodies for neuro-immune diseases
|
EP4200275A2
(en)
|
2020-08-21 |
2023-06-28 |
Sitryx Therapeutics Limited |
Fumarate derivatives and their medical use
|
WO2022040603A2
(en)
|
2020-08-21 |
2022-02-24 |
The Rockefeller University |
Single-domain antibodies that bind sars-cov-2
|
CN116322763A
(zh)
|
2020-08-27 |
2023-06-23 |
学校法人顺天堂 |
抗切断型突变calr-cd3双特异性抗体及医药组合物
|
CN116368152A
(zh)
|
2020-09-13 |
2023-06-30 |
山东博安生物技术股份有限公司 |
通过受体tac技术的膜结合蛋白的下调
|
US20230365676A1
(en)
|
2020-09-15 |
2023-11-16 |
University Of Florida Research Foundation, Incorporated |
Cd33 antibodies
|
TW202227478A
(zh)
|
2020-09-15 |
2022-07-16 |
德商拜恩迪克公司 |
對細胞靶向遞送的藥劑及方法
|
WO2022063302A1
(zh)
|
2020-09-25 |
2022-03-31 |
克莱格医学有限公司 |
免疫细胞活性调节
|
CN116390733A
(zh)
|
2020-09-28 |
2023-07-04 |
纳夫罗根公司 |
用于治疗癌症的替代性格式化的抗间皮素抗体的组合物和用途
|
EP4225797A1
(en)
|
2020-10-09 |
2023-08-16 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Binders and chimeric antigen receptors which specifically bind fibroblast growth factor receptor 4
|
US20220119549A1
(en)
|
2020-10-15 |
2022-04-21 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
|
CN116745289A
(zh)
|
2020-10-20 |
2023-09-12 |
奥洛治疗有限公司 |
游离脂肪酸受体1的激动剂及其在与所述受体相关的疾病中的用途
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|